Publications by authors named "Rachel Archer"

Claim this Profile
T
The cost of COVID-19 vaccine delivery in Bangladesh.
Afroja Yesmin, Flavia Moi, Tarek Hossain, Rachel A Archer, Monjurul Islam

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations.
Hugo C Turner, Rachel A Archer, Laura E Downey, Wanrudee Isaranuwatchai, Kalipso Chalkidou

Front Public Health· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing a Thai national critical care allocation guideline during the COVID-19 pandemic: a rapid review and stakeholder consultation.
Aniqa Islam Marshall, Rachel Archer, Woranan Witthayapipopsakul, Kanchanok Sirison, Somtanuek Chotchoungchatchai

Health Res Policy Syst· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making.
Siobhan Botwright, Anna-Lea Kahn, Raymond Hutubessy, Patrick Lydon, Joseph Biey, Rachel Archer

Vaccine X· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prioritizing critical-care resources in response to COVID-19: lessons from the development of Thailand's Triage protocol.
Rachel A Archer, Aniqa I Marshall, Kanchanok Sirison, Woranan Witthayapipopsakul, Pisit Sriakkpokin

Int J Technol Assess Health Care· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing 3 Approaches for Making Vaccine Adoption Decisions in Thailand.
Waranya Rattanavipapong, Ritika Kapoor, Yot Teerawattananon, Jos Luttjeboer, Siobhan Botwright, Rachel A Archer

Int J Health Policy Manag· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interventions to promote oral nutritional behaviours in people living with neurodegenerative disorders of the motor system: A systematic review.
Munira Essat, Rachel Archer, Isobel Williams, Nicolò Zarotti, Elizabeth Coates

Clin Nutr· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
'
'It takes two to tango': Bridging the gap between country need and vaccine product innovation.
Rachel A Archer, Ritika Kapoor, Wanrudee Isaranuwatchai, Yot Teerawattananon, Birgitte Giersing

PLoS One· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors affecting the successful implementation of Global Polio Eradication Initiative (GPEI) in low- and middle-income countries.
Suleiman E Mshelia, Chris Blackmore, Rachel Archer, Andrew Booth

J Glob Health· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of non-communicable disease: best buys, wasted buys, and contestable buys.
Wanrudee Isaranuwatchai, Yot Teerawattananon, Rachel A Archer, Alia Luz, Manushi Sharma

BMJ· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
Emma L Simpson, Shijie Ren, Emma S Hock, John W Stevens, Aymeric Binard, Rachel Archer

Int J Technol Assess Health Care· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.
Rachel Archer, Emma Hock, Jean Hamilton, John Stevens, Munira Essat

Health Technol Assess· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Iñigo Bermejo, Matt Stevenson, Rachel Archer, John W Stevens, Edward Goka

Pharmacoeconomics· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
Matt D Stevenson, Allan J Wailoo, Jonathan C Tosh, Monica Hernandez-Alava, Laura A Gibson, Rachel J Archer

J Rheumatol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock

Health Technol Assess· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.
Paul Tappenden, Shijie Ren, Rachel Archer, Rebecca Harvey, Marrissa Martyn-St James

Pharmacoeconomics· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Rachel Archer, Paul Tappenden, Shijie Ren, Marrissa Martyn-St James, Rebecca Harvey

Health Technol Assess· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock

Health Technol Assess· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Munira Essat, Paul Tappenden, Shijie Ren, Alice Bessey, Rachel Archer

Pharmacoeconomics· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Prediction Models for Lung Cancer: A Systematic Review.
Eoin P Gray, M Dawn Teare, John Stevens, Rachel Archer

Clin Lung Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ITERATIVE SIFTING IN THE SELECTION OF RESEARCH EVIDENCE: IMPLICATIONS FOR REVIEWS AND OTHER DECISION PROBLEMS.
Rachel Archer, Suzy Paisley, Munira Essat, Louise Preston, Martin Thornhill

Int J Technol Assess Health Care· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation.
Michael Holmes, John Rathbone, Chris Littlewood, Andrew Rawdin, Matt Stevenson, Rachel Archer

Health Technol Assess· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England.
Robin C Purshouse, Alan Brennan, Rachid Rafia, Nicholas R Latimer, Rachel J Archer

Alcohol Alcohol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.
Jonathan Tosh, Rachel Archer, Sarah Davis, Matt Stevenson, John W Stevens

Pharmacoeconomics· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers.
Jehangir N Din, Rachel M Archer, Scott A Harding, Jaydeep Sarma, Karin Lyall

Heart· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis